Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

BACKGROUND: Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Drugs
Main Authors: Ziemssen, Tjalf, Bass, Ann D., Berkovich, Regina, Comi, Giancarlo, Eichau, Sara, Hobart, Jeremy, Hunter, Samuel F, LaGanke, Christopher, Limmroth, Volker, Pelletier, Daniel, Pozzilli, Carlo, Schippling, Sven, Sousa, Livia, Traboulsee, Anthony, Uitdehaag, Bernard M. J., Van Wijmeersch, Bart, Choudhry, Zia, Daizadeh, Nadia, Singer, Barry A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447657/
https://ncbi.nlm.nih.gov/pubmed/32710396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-020-00749-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados